Meeting Early Phase Study Challenges – a Data Management Perspective
First-in-Human studies are a discovery point, which can decide the fate of a compound as well as lay the groundwork for subsequent phases of a...
Dasiglucagon Demonstrates Reduced Costs in the Treatment of Severe Hypoglycemia in a Budget Impact Model
admin.veranex : Mar 24, 2025 10:22:50 PM
Jordan Hinahara and Thomas Goss, members of our Commercial Strategy and Market Access team, contributed to the budget impact model. The objective was to evaluate the economic impact of dasiglucagon compared with available glucagon treatments for SHE management, considering direct cost of treatment and health care resource utilization.
Agile vs. Regulatory: How the Two Coexist and Contribute to Successful Medical Device Software Development
Gary Keeler : Mar 24, 2025 10:23:09 PM
Software is gaining relevancy in a broad range of medical devices, as it either enables the control or influence of their operation, or because...
Appropriate, early planning for medical device development could help outshine the darkness of Alzheimer’s disease
Heidi Jerman : Mar 24, 2025 10:22:46 PM
Exciting developments in the area of medical devices for the diagnosis, prognosis, treatment/management, and monitoring of Alzheimer’s disease (AD)...